Biotalys Appoints Laura J. Meyer to Board of Directors

Biotalys Appoints Laura J. Meyer to Board of Directors
Biotalys (Euronext - BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, today announced that it has appointed Laura J. Meyer to its Board of Directors and head of the Audit Committee, effective September 25, 2024. Ms. Meyer will replace Ms. Catherine Moukheibir who has decided to step down from the board.

Ms. Meyer is Vice President, Investor Relations at Bayer, with responsibility for the Crop Science division, joining the company after leading Investor Relations for Monsanto since 2014. She initially joined Monsanto (now Bayer) in 1996 and served in pivotal financial roles in technology, commercial and product management organizations during the company’s transformation to the leading agricultural input company. Her more than 28 years of experience has spanned markets worldwide, including as the divisional Chief Financial Officer for the company’s global vegetable seeds and Asia row crops businesses.

“We are delighted to have someone with Laura’s unique skill set join us at this important juncture in Biotalys’ evolution,” said Simon Moroney, Chairman of Biotalys. “Her financial and commercial background will be particularly valuable as we advance our first products and expand our research pipeline. I would like to thank Catherine Moukheibir, who will be stepping down from the board, for her invaluable contributions during an important phase of the company’s growth. We will all miss her and wish her the very best in her future endeavors.”

“Laura’s financial expertise, business acumen and excellent communications skills will allow her to make immediate and critical contributions to Biotalys, and we look forward to her engagement with the company,” added Chief Executive Officer, Kevin Helash.

“I am excited and honored to join the board of Biotalys. I am passionate about agriculture and the demand for novel, sustainable solutions, like those offered by the AGROBODY technology platform, has never been greater,” said Ms. Meyer. “I am eager to contribute to another wave of transformative technologies for farmers around the globe.”

Ms. Meyer holds a Bachelor of Science degree in Accounting from the University of Missouri-Columbia. A native of St. Charles, Missouri, she began her career as a CPA with Deloitte.

Ms. Meyer meets the requirements of an independent director, and the Board of Directors expressly confirms that it has no indication of any element that could call into question the independence of Ms. Meyer. Her appointment as independent director will be proposed for confirmation at the next shareholders meeting in accordance with article 7:88 of the Belgian Code of Companies and Associations.

About Biotalys

Biotalys is an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for the protection of crops and food and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys is developing a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and has been listed on Euronext Brussels since July 2021. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.

For further information, please contact:

Toon Musschoot, Head of IR & CommunicationT: +32 (0)9 274 54 00E: IR@biotalys.com

Important Notice

Biotalys, its business, prospects and financial position remain exposed and subject to risks and uncertainties. A description of and reference to these risks and uncertainties can be found in the annual report on the consolidated annual accounts published on the company’s website.

This announcement contains statements which are "forward-looking statements" or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words ‘aim’, 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. Biotalys’ actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.

Attachments